Impaired responsiveness of renal sensory nerves in streptozotocin-treated rats and obese Zucker diabetic fatty rats: Role of angiotensin

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 294, Issue 3, 2008, Pages

  Kopp, Ulla C ^a,b   Cicha, Michael Z ^a   Yorek, Mark A ^a  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Kidney; Neuropathy; Prostaglandin; Substance P

Indexed keywords

ANGIOTENSIN; LOSARTAN; PROSTAGLANDIN E2; STREPTOZOCIN; SUBSTANCE P;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; KIDNEY NERVE; MALE; NERVE CONDUCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SENSORY NERVE; SODIUM URINE LEVEL; ZUCKER DIABETIC FATTY RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSINS; ANIMALS; BAROREFLEX; CAPSAICIN; DIABETES MELLITUS, EXPERIMENTAL; DINOPROSTONE; KIDNEY; LOSARTAN; MALE; MECHANORECEPTORS; NEURONS, AFFERENT; OBESITY; RATS; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER; SUBSTANCE P;

EID: 40449140446     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00830.2007     Document Type: Article

References (58)

1. Alonso-Galacia M, Brands MW, Zappe DH, Hall JE. Hypertension in obese Zucker rats. Hypertension 28: 1047-1054, 1996.
2. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol Renal Fluid Electrolyte Physiol 265: F477-F486, 1993.
3. Bakris Weir MR GL, Sowers JR. Therapeutic challenges in the obese diabetic patient with hypertension. Am J Med 101: 33S-46S, 1996.
4. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J. Angiotensin-receptor blockade versus converting enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351: 1952-1961, 2004.
5. Baylis C, Atzpodien EA, Freshour G, Engels K. Peroxisome proliferation-activated receptor γ agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther 307: 854-860, 2003.
6. Bell TD, DiBona GF, Wang Y, Brands MW. Mechanisms for renal blood flow control early in diabetes as revealed by chronic flow measurement and transfer function analysis. J Am Soc Nephrol 17: 2184-2192, 2006.
7. Brewster WJ, Diemel LT, Leach RM, Tomlinson DR. Reduced sciatic nerve substance P and calcitonin gene-related peptide in rats with short-term diabetes or central hypoxaemia co-exist with normal messenger RNA levels in the lumbar dorsal root ganglia. Neuroscience 58: 323-330, 1994.
8. Carlson SH, Shelton J, White CR, Wyss JM. Elevated sympathetic activity contributes to hypertension and salt sensitivity in diabetic obese Zucker rats. Hypertension 35: 403-408, 2000.
9. Chien CT, Chien HF, Cheng YJ, Chen CF, Hsu SM. Renal afferent signaling diuretic response is impaired in streptozotocin-induced diabetic rats. Kidney Int 57: 203-214, 2000.
10. Coppey LJ, Davidson EP, Rinehart TW, Gellett JS, Oltman CL, Lund DD, Yorek MA. ACE inhibitor or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetes 55: 341-348, 2006.
11. Daneman D. Type 1 diabetes. Lancet 367: 847-858, 2006.
12. DeFronzo RA. The triumvirate: β-cell, muscle and liver. A collusion responsible for NIDDM. Diabetes 37: 667-687, 1988.
13. Harrison-Bernard LM, Imig JD, Carmines PK. Renal AT1 receptor protein expression during the early stage of diabetes mellitus. Int J Exp Diab Res 3: 97-108, 2002.
14. Hoshi S, Shu Y, Yoshida F, Inagaki T, Sonoda J, Watanabe T, Nomoto K, Nagata M. Podocyte injury promotes progressive nephropathy in Zucker diabetic fatty rats. Lab Invest 82: 25-35, 2002.
15. Kopp UC, Cicha MZ. Impaired substance P release from renal sensory nerves in SHR involves a pertussis toxin sensitive mechanism. Am J Physiol Regul Integr Comp Physiol 286: R326-R333, 2004.
16. 2 mediated stimulation of renal sensory nerves. Am J Physiol Renal Physiol 287: F1269-F1282, 2004.
17. Kopp UC, Cicha MZ, Farley DM, Smith LA, Dixon BS. Renal substance P containing neurons and substance P receptors impaired in hypertension. Hypertension 31: 815-822, 1998.
18. 2-mediated activation of cAMP. Am J Physiol Renal Physiol 285: F472-F483, 2003.
19. Kopp UC, Cicha MZ, Smith LA. Arterial pressure increases in afferent renal denervated rats on high sodium diet. Hypertension 42: 968-973, 2003.
20. 2-mediated release of substance P from renal mechanosensory nerve fibers. Am J Physiol Regul Integr Comp Physiol 282: R19-R30, 2002.
21. Kopp UC, Cicha MZ, Smith LA. Impaired responsiveness of renal mechanosensory nerves in heart failure: role of endogenous angiotensin. Am J Physiol Regul Integr Comp Physiol 284: R116-R124, 2003.
22. 2 increases release of substance P from renal sensory nerves by activating the cAMP-PKA transduction cascade. Am J Physiol Regul Integr Comp Physiol 282: R1618-R1627, 2002.
23. Kopp UC, Cicha MZ, Smith LA, Haeggström JZ, Samuelsson B, Hökfelt T. Cyclooxygenase-2 involved in stimulation of renal mechanosensitive neurons. Hypertension 35:373-378, 2000.
24. 2- adrenoceptors on renal sensory nerve fibers. Am J Physiol Regul Integr Comp Physiol 293: R1561-R1572, 2007.
25. 2 and substance P. Am J Physiol Regul Integr Comp Physiol 278: R937-R946, 2000.
26. Kopp UC, Olson LA, DiBona GF. Renorenal reflex responses to mechano-and chemoreceptor stimulation in the dog and rat. Am J Physiol Renal Fluid Electrolyte Physiol 246: F67-F77, 1984.
27. +-ATPase inhibition sensitizes renal mechanoreceptors activated by increases in renal pelvic pressure. Am J Physiol Regul Integr Comp Physiol 267: R1109-R1117, 1994.
28. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist ibesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001.
29. Liu L, Barajas L. The rat renal nerves during development. Anat Embryol (Berl) 188: 345-361, 1993.
30. Marsh SA, Powell PC, Agarwal A, Dell'Ítalia LJ, Chatham JC. Cardiovascular dysfunction in Zucker obese and Zucker diabetic fatty rats: role of hydronephrosis. Am J Physiol Heart Circ Physiol 293: H292-H298, 2007.
31. Maxfield EK, Cameron NE, Cotter MA, Dines KC. Angiotensin II receptor blockade improves nerve function, modulates nerve blood flow and stimulates endoneural angiogenesis in streptozotocin-diabetic rats and nerve function. Diabetologia 36: 1230-1237, 1993.
32. Miller JA. Impact of hyperglycemia on the renin angiotensin system in early human type I diabetes mellitus. J Am Soc Nephrol 10: 1778-1785, 1999.
33. Mizuno M, Sada T, Kato M, Fukushima Y, Terashima H, Koike H. The effect of angiotensin II receptor blockade on an end-stage renal failure model of type 2 diabetes. J Cardiovasc Pharmacol 48: 135-142, 2006.
34. Morgan DA, Anderson EA, Mark AL. Renal sympathetic nerve activity is increased in obese Zucker rats. Hypertension 25: 834-838, 1995.
35. Nagai Y, Yao L, Kobori H, Miyata K, Ozawa Y, Miyatake A, Yukimura T, Shokoji T, Kimura S, Kiyomoto H, Kohno M, Abe Y, Nishiyama A. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 16: 703-711, 2005.
36. Oltman CL, Coppey LJ, Gellett JS, Davidson EP, Lund DD, Yorek MA. Progression of vascular and neural dysfunction in sciatic nerves of Zucker diabetic and Zucker rats. Am J Physiol Endocrinol Metab 289: E113-E122, 2005.
37. Oltman CL, Davidson EP, Coppey LJ, Kleinschmidt TL, Lund DD, Adebara ET, Yorek MA. Vascular and neural dysfunction in Zucker diabetic fatty rats: a difficult condition to reverse. Diabetes Obes Metab doi:10.1111/j.1463-1236, 2007.00814.
38. Patel KP, Carmines PK. Renal interstitial hydrostatic pressure and sodium excretion during acute volume expansion in diabetic rats. Am J Physiol Regul Integr Comp Physiol 281: R239-R245, 2001.
39. Patel KP, Zhang PL. Reduced renal sympathoinhibition in response to acute volume expansion in diabetic rats. Am J Physiol Regul Integr Comp Physiol 267: R372-R379, 1994.
40. Peterson RG, Neel MA, Little LA, Kincaid JC, Eichberg J. Neuropathic complications in the Zucker diabetic fatty rat (ZDF/Drt-fa). In: Frontiers in Diabetic Research. Lessons from Animal Diabetes III, edited by Shafrir E. London: Smith-Gordon, 1990, p. 456-458.
41. Peterson RG, Shaw WN, Neel MA, Little LA, Eichberg J. Zucker diabetic fatty rat as a model for non-insulin-dependent diabetes mellitus. ILAR NEWS 32: 16-19, 1990.
42. Ruiz J, Monbaron D, Parati G, Perret S, Haesler E, Danzeisen C, Hayoz D. Diabetic neuropathy is a more important determinant of baroreflex sensitivity than carotid elasticity in type 2 diabetes. Hypertension 46: 162-167, 2005.
43. Salgado HC, Fazan R, Fazan VPS, DaSilva VJD, Barreira AA. Arterial baroreceptors and experimental diabetes. Ann NY Acad Sci 940: 20-27, 2001.
44. Sanya EO, Brown CM, Dütsch Zikeli B, Neuendörfer Hilz MJ. Impaired cardiovagal and vasomotor responses to baroreceptor stimulation in type II diabetes mellitus. Eur J Clin Invest 33: 582-588, 2003.
45. Schreihofer AM, Mandel DA, Mobley SC, Stepp DW. Impairment of sympathetic baroreflexes in obese Zucker rats. Am J Physiol Heart Circ Physiol 293: H2543-H2549, 2007.
46. Shafir E. Animal models of non-insulin-dependent diabetes. Diabetes Metab Rev 8: 179-208, 1992.
47. Sharma R, Sharma M, Reddy S, Savin VJ, Nagaria AM, Wiegman TB. Chronically increased intrarenal angiotensin II causes neuropathy in an animal model of type 2 diabetes. Front Biosci 11: 968-976, 2006.
48. Siegel S, Castellan N Jr. Nonparametric Statistics for the Behavioral Sciences, 2nd edition. New York: McGraw-Hill, 1988, p. 87-95, 103-111, 128-137, 174-183.
49. Sima AAF, Sugimoto K. Experimental diabetic neuropathy: an update. Diabetologia 42: 773-788, 1999.
50. Suzaki Y, Ozawa Y, Kobori H. Intrarenal oxidative stress and augmented angiotensinogen are precedent to renal injury in Zucker diabetic fatty rats. Int J Biol Sci 3: 40-46, 2007.
51. Tallam LS, Jandhyala BS. Significance of exaggerated natriuresis after angiotensin AT1 receptor blockade or angiotensin-converting enzyme inhibition in obese Zucker rats. Clin Exp Pharmacol Physiol 28: 433-440, 2001.
52. Tate MW, Clelland RC. Nonparametric and Shortcut Statistics in the Social, Biological Sciences. Danville, IL: Interstate, 1957, p. 111-113, 120-121.
53. Troger J, Humpel C, Kremser B, Kralinger M, Teuchner B, Kunze C, Philipp W, Kieselbach G. The effect of streptozotocin-induced diabetes mellitus on substance P and calcitonin gene-related peptide expression in the rat trigeminal ganglion. Brain Res 842: 84-91, 1999.
54. Troger J, Neyer S, Heufler C, Huemer H, Schmidt E, Griesser U, Kralinger M, Kremser B, Baldissera I, Kieselbach G. Substance P and vasoactive intestinal polypeptide in the streptozotocin-induced diabetic rat retina. Invest Ophthalmol Vis Sci 42: 1045-1050, 2001.
55. Tuck ML, Corry DB. Pathophysiology and management of hypertension in diabetes. Annu Rev Med 42: 533-548, 1991.
56. Ustinova EE, Barrett CJ, Sun SY, Schultz HD. Oxidative stress impairs cardiac chemoreflexes in diabetic rats. Am J Physiol Heart Circ Physiol 279: H2176-H2187, 2000.
57. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 26: 1553-1579, 2003.
58. Vora JP, Zimsen SM, Houghton DC, Anderson S. Evolution of metabolic and renal changes in the ZDF/Drt-fa rat model of type II diabetes. J Am Soc Nephrol 7: 113-117, 1996.